Whitehawk Therapeutics Inc. outlined its antibody-drug conjugate platform featuring a cleavable linker and a proprietary topoisomerase 1 inhibitor payload in a DAR6 configuration, along with high-affinity antibody selection and an attenuated Fc region. The company highlighted a three-asset portfolio: HWK-007 targeting PTK7, HWK-016 targeting MUC16, and HWK-206 targeting SEZ6, with initial Phase 1 programs planned across multiple solid tumor indications and a planned Phase 1 for HWK-206 in small cell lung cancer and neuroendocrine neoplasms. The presentation also discussed preclinical data on potency, stability and safety measures, and described clinical development plans with first data readouts anticipated in early 2027 for HWK-007 and HWK-016. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.